Advertisement
To access a simultaneous webcast of the presentation via the internet, logon to the "Events & Presentations" section of the Investor Center onPharmasset's website at http://investor.pharmasset.com/events.cfm . Pleaseconnect to the website at least ten minutes prior to the start of thepresentation to ensure adequate time for a reliable connection and anysoftware download that may be necessary for the webcast.
Advertisement
The archived replay of the webcast will be available on Pharmasset'swebsite for a limited period of time following the conference. The investorpresentation will be available for download in PDF format following thepresentation in the "Events & Presentations" section of the Investor Center onPharmasset's website at http://investor.pharmasset.com/events.cfm .
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed todiscovering, developing and commercializing novel drugs to treat viralinfections. Pharmasset's primary focus is on the development of oraltherapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,for the treatment of chronic HBV infection, is enrolling Phase 3 clinicaltrials for registration in North, Central and South America and Europe.Clevudine is already approved for HBV in South Korea and marketed by BukwangPharmaceuticals in South Korea under the brand name Levovir. R7128, an oraltreatment for chronic HCV infection, is in a 4 week Phase 1 clinical trial incombination with Pegasys(R) and Copegus(R) through a strategic collaborationwith Roche. Racivir, which is being developed for the treatment of HIV incombination with other approved HIV drugs, has completed a Phase 2 clinicaltrial.
SOURCE Pharmasset, Inc.